Home New Customer? Create Account
Member Login:

Neomycin/G418/Geneticin Selection Plasmids

OG396 - pSF-CMV-PGK-Neo/G418


Starting at: $307.00

Please Choose:

Shipping Option

Enter Quantity:

Sequence (txt)

This plasmid is compatible with all of the other DNA sequences available on this site, which are all sold in the same backbone. This flexibility allows you to create any vector you require, with a variety of functions, simply by compiling the relevant sections from our product range.

Vector: pSF-CMV-PGK-Neo G418 

Product Code: 

Quantity Provided: 5µg

Size (bp): 5536

Bacterial Antibiotic Selection: Kanamycin

Origin and Compatibility: pUC high copy, derived from pBR322   

Copy Number: 500-700 copies per cell

Promoter: Cytomegalovirus (CMV) immediate early promoter and the mouse phosphoglycerate kinase promoter (PGK)

Purpose: This plasmid contains two promoters that terminate transcription at the same poly adenylation signal, allowing the expression of two genes from one expression cassette, where the second gene is the Neomycin/G418 resistance gene (Neo/G418) for antibiotic selection in mammalian cells. The second promoter (PGK) is approximately 10-fold weaker than the upstream CMV promoter in most commonly used cell lines. 

G418 Selection notes: Although the gene name in this vector is neo, neomycin cannot be used in mammalian, or other eukaryotic cells, because it is ineffective at inhibiting eukaryotic ribosomes. For this reason, the plasmid must be selected in mammalian cells using G418 (otherwise known as Geneticin). The neo gene will induce resistance to kanamycin, neomycin and G418 in bacterial cells, however, in this vector the gene is not designed to express in bacteria, and hence will offer no resistance

Quality Validation: This vector has been demonstrated to express reporter genes to high levels under the CMV promoter. The start codon of these reporters was positioned within the NcoI site and the stop codon was positioned within the XbaI site. This plasmid also demonstrates resistance to G418. Expression and selection has been validated in 293 cells.   

Quality Sequencing Analysis: This vector has been fully sequenced using primers F1-F10. The sequences and details of these primers are available through our website.

Intellectual Property Status: According to our IP-friendly policy, this plasmid is sold free of reach-through rights on any derivatives you may create.

Genetic Modifications to standard parts:

  • CMV promoter – an NcoI site has been ablated in the CMV promoter. This change does not reduce expression.
  • KanR cassette – This KanR resistance region is not a wild type sequence, it has been modified to remove all restriction sites that conflict with the SnapFast system and to retain a high level of antibiotic resistance. It has been validated in E.coli.
  • The Neo/G418 gene has been modified to remove NcoI, EagI, PstI and SphI sites to ensure compatibility with all of our products. These are all conservative changes and do not change the amino acid sequence.   

Restriction site notes:

  • Bgl2, KpnI, SwaI and PmeI each cut the vector at two sites positioned to flank the promoter, start codon, origin, and KanR, respectively.
  • BsgI and BseRI recognise non-palindromic DNA sequences and cleave upstream of their recognition sites, within the stop codon that is found inside the XbaI restriction site.